Valink Therapeutics
Winter 2021 · Active
Discovering bispecific antibody drug-conjugates (BsADC) against cancer
Location: Boston, US
Founded: 2021
Team size: 15
Industries:
About
Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.
Founders
Arne ScheuFounder
Rhodes Scholar & DPhil Biochemistry from the University of Oxford
Irsyad KhairilFounder
Pharma analyst with a background in protein engineering DPhil in Biochemistry from the University of Oxford